Purchase this article with an account.
S.M. Podos, R. Wang, J.L. Boyer, B.R. Yerxa, J.B. Serle; Effect of the P2Y14 Receptor Agonist, UDP-Glucose, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4404.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: The UDP-glucose receptor (P2Y14 receptor) is a recently identified member of the nucleotide receptor family. This study evaluates the effect of topical application of UDP-glucose on IOP in monkey eyes with laser-induced unilateral glaucoma. Methods: A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 25 µl drop of UDP-glucose (3%) was applied topically to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hrs beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and treatment days 1, 3, and 5 with UDP-glucose. Results: Compared to vehicle treatment, twice daily administration of UDP-glucose for 5 days reduced (p<0.05) IOP from 1 hr to 4 hr after the first dose and for at least 6 hrs after the fifth dose. The maximum reduction (p<0.001) of IOP occurred 2 hrs after morning dosing, and was 3.3 ± 0.6 mm Hg (9%) (mean ± SEM) on day 1, 3.8 ± 0.5 mmHg (10%) on day 3, and 5.0 ± 0.6 mmHg (14%) on day 5. The ocular hypotensive effect increased with repeated dosing. The IOP reduction was greater (p<0.05) at 5 and 6 hrs on day 3 compared to day 1 of treatment, and at 0 and 2 hours on day 5 compared to day 3 of treatment. Adverse ocular or systemic side effects were not observed during the 5 days of treatment. Conclusion: UDP-glucose reduces IOP in glaucomatous monkey eyes. Additional investigations of this nucleotide receptor agonist are warranted.
This PDF is available to Subscribers Only